Form 4: Kura Oncology Chief Medical Officer Reports Stock and Option Grants

Mollie Leoni, Chief Medical Officer of Kura Oncology, reported the acquisition of restricted stock units and stock options.

Summary

• Mollie Leoni, Chief Medical Officer of Kura Oncology, has reported a transaction involving the acquisition of company securities.
• On January 2, 2025, Ms. Leoni was granted 46,250 restricted stock units (RSUs).
• These RSUs will vest in four equal annual installments starting on January 26, 2026, and continuing until January 26, 2029.
• Additionally, Ms. Leoni was granted an option to purchase 92,500 shares of common stock at an exercise price of $8.68.
• This option vests in 48 equal monthly installments starting from the grant date and expires on January 1, 2035.
• Following these transactions, Ms. Leoni directly owns 93,216 shares of common stock and options to purchase 92,500 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation, which is generally positive for aligning management interests with shareholders. There are no negative implications.

Positives

• The grant of RSUs and stock options to the Chief Medical Officer aligns her interests with the long-term success of the company.
• The vesting schedules for both the RSUs and options encourage continued service and performance.

Industry Context

This type of equity compensation is common in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Equity grants are a standard practice for executive compensation in the biotech industry, often including a mix of stock options and restricted stock units.
• Vesting schedules, such as the four-year vesting for RSUs and monthly vesting for options, are typical to incentivize long-term commitment.
• The specific amounts and terms of the grants would need to be compared to peer companies to determine if they are above or below industry averages.

Stakeholder Impact

• The equity grants may have a minor dilutive effect on existing shareholders.
• The grants are intended to motivate the Chief Medical Officer, which could benefit shareholders through improved company performance.

Key Dates

Keywords

stock options, restricted stock units, insider trading, form 4, Kura Oncology, equity compensation, Mollie Leoni